The heart attack diagnostics market was estimated to reach USD 6.6 billion in 2015. Heart attack or myocardial infarction is a form of cardiovascular disease (CVD) and it occurs when oxygenated blood flow to the heart muscle is reduced or cut off, which is also termed as myocardial ischemia. It is one of the leading causes of death, globally, and poses an alarmingly high burden and risk factor. An exigent nature of a myocardial infarction necessitates rapid diagnosis and treatment. The most predominant risk factor responsible for the occurrence of heart attacks in humans is the adoption of unhealthy lifestyle habits including suboptimal diets, followed by tobacco smoking, high body mass index, sedentary lifestyles, and the presence of chronic diseases, such as diabetes and hypertension in the population. These risk factors lead to the deposition or a buildup of fat, cholesterol, and other substances, hence narrowing the coronary arteries supplying the heart, resulting in atherosclerosis or Coronary Artery Disease (CAD). As research data suggests, at every interval of 43 seconds, a U.S citizen suffers from a heart attack.
Global Heart Attack Diagnostics Market, By Region, 2013-2024, (USD Million)
The drivers influencing the growth of the market are the high prevalence of CAD, an increasing geriatric population base, and obesity in individuals stemming from tobacco smoking &the adoption of unhealthy diets leading to the incidence of high cholesterol. However, the low reimbursement provided for mobile cardiac outpatient telemetry ECG by the U.S. government and the gradually declining heart attack incidence rates is expected to hinder the growth of this vertical in the forecast period.
The heart attack diagnostics market by test type is segmented into Electrocardiogram (ECG or EKG), blood tests, and others. The blood tests segment comprises of troponin, Creatine Kinase MB Isoenzyme (CK-MB), and others. The diagnostic methods that belong in the others category include chest radiography, coronary angiography, echocardiogram, and Positron-Emission Tomography (PET) scanning.
ECG is the most commonly employed method for the diagnosis of heart attacks and is continually evolving with progressive technological improvements thus resulting in wider applications. ECGs monitoring systems, event monitors, implantable loop recorders, cardiac telemetry, and ECG data management solutions are the latest additions contributing to the growth of the ECG market transforming it into a technologically powerful and profitable segment. This segment is expected to grow at a significant rate given the high usage rates of ECG in treating CVDs, thus acting as a major driver for this vertical.
With the advent of technology in diagnostics, the blood tests are gradually acquiring the market share of ECG in the heart attack diagnostics market. Blood tests such as troponin are considered as the gold standard method in diagnosis of myocardial infarction owing to its rapid, accurate results, with low turnaround time. As of 2015, troponin test is estimated to hold majority of the shares in the blood tests segment as is anticipated to grow at the highest CAGR during the forecast period.
The key regions considered in the heart attack diagnostics market are North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is estimated to dominate the global heart attack diagnostics market. The increasing awareness about myocardial infarction, its causes and risk factors, has imposed a positive impact on the market. The U.S. represents the largest market for heart attack diagnostics, followed by Germany.
The Asia Pacific region is expected to be the fastest growing region during the forecast period attribute able to the large burden of heart diseases in certain regions and the presence of highly populated countries including India and China, which are estimated to drive the market growth in the near future. According to published reports, India leads the Asia Pacific segment owing to the high incidence of heart attacks and soaring death rates due to heart diseases.
The major players leading the industry are Siemens Healthcare GmbH, Schiller AG, Midmark Corporation, Koninklijke Philips N.V., Bionet Co., Ltd., Welch Allyn, Toshiba Medical Systems Corporation, Mortara Instrument, and Hitachi Medical Systems. These companies are driven by diverse strategies and are focused toward new test type development and consistent technological advances coupled with continuous product modifications. For instance, in August 2015, Schiller AG launched the CARDIOVIT FT-1, an ultra-portable ECG device, which features an intuitive 8-inch multi-touch screen with high resolution display integrated with a thermal printer.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.